Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A building project to extend the Kennedy Institute of Rheumatology building with a new floor will create much needed space for the Institute to expand, particularly in the areas of data science and clinical trials.

Kennedy Institute building
The new floor will enable the Institute to expand its data science and clinical trials programmes

Housing more than 25 research groups, the Kennedy Institute of Rheumatology is at the forefront of research in the areas of immunity and microbiome, inflammation biology, and tissue remodelling and regeneration. Approximately 200 researchers, support staff and students work towards making fundamental discoveries about biological processes that help in the understanding of inflammatory and degenerative diseases such as rheumatoid arthritis, osteoarthritis, inflammatory bowel disease and cancer.

A strategic objective of the Institute is to accelerate understanding of these diseases through the application of data science-based approaches complementing its long-established lab-based research. The Institute has invested substantially in this area, building a core of expertise and technologies encompassing single cell genomics, statistical genetics, microbial genomics, computational biology and clinical trials.

The full story is available on the Nuffield Department of Orthopaedics,Rheumatology & Musculoskeletal Sciences website

Similar stories

Peter Horby receives prestigious award for outstanding service to public health

The Faculty of Public Health (FPH) has awarded its prestigious Alwyn Smith Prize to Professor Sir Peter Horby (Nuffield Department of Medicine) for 2020/2021 in recognition of his outstanding service to public health as a global leader in epidemic science.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Professor Trish Greenhalgh Highly Commended in the O²RB Excellence in Impact Awards 2021

Congratulations to Professor Trish Greenhalgh (Nuffield Department of Primary Care Health Sciences) who has been Highly Commended in the O²RB Excellence in Impact Awards 2021.

No benefit of convalescent plasma for critically ill COVID-19 patients

A large study of over 2000 COVID-19 patients has found that giving critically ill patients blood plasma from recovered COVID-19 patients did not significantly reduce deaths, or the need for intensive care support such as being put on a ventilator machine.